Dr Gary Lichtenstein and colleagues of Pennsylvania, USA compared the long-term safety of infliximab and nonbiologic agents as Crohn’s disease therapy.
Patients with Crohn’s disease were prospectively evaluated in this large, observational registry.
Patients participated in this observational registry from 1999 through 2012, of which 3440 received infliximab and 2833 received other treatments only.
Overall, 59,875 infliximab infusions were administered; 3006 patients received ≥2 infusions.
The team found that adverse events, most commonly those related to Crohn’s disease and serious adverse events occurred at a higher rate among infliximab-treated patients.
Mortality and malignancy rates for infliximab-treated and other-treatments-only patients, respectively, were generally similar.
|An increased risk of serious infection was observed with age
|Inflammatory Bowel Diseases
The team discovered serious infection rates were higher for infliximab-treated than other-treatments-only patients.
Infliximab dose was not associated with mortality or serious infection.
An increased risk of serious infection was observed with age when examined in infliximab-treated patients.
Nonserious cerebrovascular accidents and pulmonary embolisms also occurred at higher rates among infliximab-treated patients than other-treatments-only patients.
Dr Lichtenstein's team concluded, "Through more than 13 years of registry experience and an overall median duration of patient follow-up >6 years, mortality was similar between the infliximab-treated and other-treatments-only groups."
"These final cumulative results are representative of real-world experience among infliximab-treated patients with Crohn’s disease and are consistent with the known risks of disease activity and tumor necrosis factor antagonist therapy."